Does Health Net Cover Eliquis?

What Is Eliquis and Why Is Coverage Important?

Eliquis is the brand name for apixaban, a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa. The FDA first approved apixaban in December 2012 for reducing stroke risk in non-valvular atrial fibrillation, then extended that approval to treatment and secondary prevention of deep-vein thrombosis (DVT) and pulmonary embolism (PE). [1]

Anticoagulation is not optional for most patients who carry these diagnoses. Untreated atrial fibrillation carries an annual stroke risk of roughly 3 to 5% in intermediate-risk patients, and the 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline states that "oral anticoagulation is recommended for patients with AF and a CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women." [2] Missing doses because of cost directly raises that risk.

Why Apixaban Specifically

The ARISTOTLE trial (N=18,201) found that apixaban reduced stroke or systemic embolism by 21% compared with warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.94, P<0.001 for superiority), with a simultaneous 31% reduction in major bleeding. [3] Those numbers are why physicians often prefer apixaban over warfarin despite the price difference.

No Generic Means Higher Tier Placement

Because no FDA-approved generic apixaban existed as of early 2025, Health Net cannot place the drug on a low-cost generic tier the way it can with warfarin. That structural fact, not any administrative decision about Eliquis specifically, is what pushes apixaban to Tier 3 or Tier 4 on most Health Net formularies.

How Health Net Formularies Work

Health Net operates several distinct product lines: commercial PPO and HMO plans sold through employers or directly, Medicare Advantage plans (Health Net's Medicare offerings use the SilverScript or Health Net brand depending on region), and Medi-Cal managed-care plans in California. Each product line maintains a separate formulary, and tier placement can differ across them.

Tiers and What They Cost

Most Health Net commercial plans use a four- or five-tier structure:

• Tier 1, preferred generics (lowest copay, often $5, $15)
• Tier 2, non-preferred generics or preferred brands (typically $30, $50)
• Tier 3, preferred brand-name drugs (typically $47, $100)
• Tier 4, non-preferred brand-name drugs (typically $100, $200+)
• Tier 5, specialty drugs (coinsurance, often 25 to 33% of drug cost)

Eliquis most commonly appears at Tier 3 or Tier 4 in Health Net commercial formularies reviewed for plan year 2024 to 2025. Your Summary of Benefits document, accessible through your Health Net online member portal, will show the exact tier and copay for your specific plan.

Formulary Exceptions

If your prescriber believes a lower-tier alternative is medically inappropriate, they can request a formulary exception. Health Net is required under federal regulations to process standard exception requests within 72 hours and expedited (urgent) requests within 24 hours. [4] A successful exception can move your cost-sharing down by one full tier.

Prior Authorization: What Health Net Requires

Prior authorization (PA) for Eliquis on Health Net plans typically requires the prescriber to document:

1. The FDA-approved diagnosis (AF, DVT, PE, or post-surgical prophylaxis)
2. A CHA₂DS₂-VASc score of 2 or higher for AF patients, or confirmed imaging/lab evidence for DVT/PE
3. Clinical rationale if the prescriber is not starting with a lower-cost anticoagulant such as warfarin

The PA process adds 1 to 5 business days before the pharmacy can fill the prescription. Patients in acute DVT/PE treatment should ask the prescriber to file an expedited PA request on the same day as the office visit.

What If PA Is Denied?

A denial is not final. Health Net's internal appeals process allows a first-level appeal, reviewed by a Health Net medical director, within 30 days for standard appeals or 72 hours for expedited appeals. [4] If the internal appeal fails, members have the right to an Independent Medical Review (IMR) through the California Department of Managed Health Care (for California residents) or the relevant state insurance commissioner.

Step Therapy Considerations

Some Health Net plans apply step therapy, meaning the plan wants evidence that a patient has tried and failed (or is contraindicated to) a preferred anticoagulant before approving Eliquis. Common step-therapy alternatives required include warfarin and, on some formularies, rivaroxaban (Xarelto). Prescribers should document INR instability, drug interactions, or patient preference based on the once-daily versus twice-daily dosing comparison when making the case to skip the step.

Eliquis Dosing and Approved Indications Relevant to Coverage Decisions

Health Net PA reviewers assess whether the requested dose matches an FDA-labeled indication. Prescribers should match the exact labeled dose to avoid automatic denials.

FDA-Approved Doses

| Indication | Approved Dose | |---|---| | Non-valvular AF stroke prevention | 5 mg twice daily (2.5 mg twice daily if ≥2 dose-reduction criteria met) | | DVT/PE treatment (first 7 days) | 10 mg twice daily | | DVT/PE treatment (after 7 days) | 5 mg twice daily | | DVT/PE extended prevention | 2.5 mg twice daily | | Post-knee or hip replacement prophylaxis | 2.5 mg twice daily |

Source: FDA prescribing information for Eliquis. [1]

The 2.5-mg dose-reduction criteria for AF are: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (any two of these three criteria trigger the lower dose). Submitting a PA for 5 mg twice daily in a patient who meets two of those criteria will trigger a medical necessity review.

How Much Will You Actually Pay?

Cost depends on four variables: your Health Net plan tier, whether you have met your deductible, whether you use a preferred pharmacy, and whether you qualify for manufacturer assistance.

Without Any Assistance

The average retail price for a 30-day supply of Eliquis 5 mg twice daily (60 tablets) exceeded $600 at most major pharmacies in 2024, according to publicly available pharmacy pricing data. On a Tier 3 Health Net plan with a $60 branded copay and a met deductible, you would pay $60. On a Tier 4 plan mid-deductible year, you could owe the full cost-sharing until you hit your out-of-pocket maximum.

Bristol-Myers Squibb / Pfizer Savings Card

The Eliquis manufacturers offer a co-pay card that caps monthly cost at $10 for commercially insured patients who meet income and eligibility criteria. Patients with Medicare, Medicaid, or other federal health programs cannot use this card. Enrollment is at eliquis.com or by calling 1-855-ELIQUIS. [5]

Medicare Part D Patients on Health Net

For patients enrolled in a Health Net Medicare Advantage Prescription Drug (MAPD) plan, Eliquis coverage falls under Part D rules. The 2025 Medicare Part D redesign, mandated by the Inflation Reduction Act, capped annual out-of-pocket drug spending at $2,000 for all Part D enrollees starting January 1, 2025. [6] That cap meaningfully changes the calculus for high-cost brand drugs like Eliquis.

Medi-Cal Managed Care (Health Net California)

Health Net administers Medi-Cal managed care in several California counties. Medi-Cal beneficiaries generally have a $0 or very low copay for formulary drugs; however, Eliquis still requires PA under Medi-Cal Drug Utilization Review criteria. The Drug Effectiveness Review Project and California's Drug Utilization Review board both support DOACs as preferred therapy for AF in Medi-Cal guidelines. [7]

Step-by-Step: How to Get Eliquis Covered by Health Net

Getting a prior authorization approved is not complicated if each step is handled in the right order.

Step 1: Confirm Your Plan's Formulary Tier

Log into your Health Net member portal or call Member Services (the number is on the back of your insurance card). Ask specifically: "Is apixaban (Eliquis) on my formulary, what tier, and does it require PA?"

Step 2: Have Your Prescriber Submit a PA Request

The prescriber's office should submit the PA through Health Net's online portal or fax. The request should include the ICD-10 diagnosis code (I48.x for AF, I82.x for DVT, I26.x for PE), supporting lab or imaging, and the specific dose requested.

Step 3: Use the Manufacturer Savings Card If Commercially Insured

If you have commercial insurance (not Medicare or Medicaid), register for the BMS/Pfizer co-pay card before picking up the first fill. The card reduces your out-of-pocket cost regardless of your tier placement, down to as little as $10/month. [5]

Step 4: Appeal If Denied

Request a written denial letter with the specific medical criteria used. Your prescriber should write a peer-to-peer appeal letter citing the ARISTOTLE trial results [3] and the ACC/AHA guideline recommendation for anticoagulation in your patient's CHA₂DS₂-VASc category. [2]

Step 5: Request an Independent Medical Review

California residents can file an IMR request with the California Department of Managed Health Care (DMHC) within 180 days of a final internal appeal denial. The DMHC overturns approximately 30% of reviewed IMR cases in the patient's favor, per annual DMHC activity reports. [8]

Clinical Context: Why Switching Off Eliquis Is Not Always Safe

Some patients and prescribers consider switching to warfarin solely to reduce cost. That trade-off deserves careful analysis.

Bleeding and Efficacy Differences

The ARISTOTLE trial showed a statistically significant reduction in intracranial hemorrhage with apixaban versus warfarin (0.33% vs. 0.80% per year, P<0.001). [3] Intracranial bleeding is the most feared anticoagulation complication and carries a 30-day mortality rate of roughly 30 to 40%. [9] For patients with a history of falls, prior intracranial hemorrhage, or labile INRs, switching to warfarin to save money may represent a clinically meaningful safety downgrade.

INR Monitoring Burden

Warfarin requires regular INR monitoring, typically every 4 weeks once stable, with dose adjustments for food-drug and drug-drug interactions. The 2023 AF guideline notes that "patients with difficulty maintaining a therapeutic INR should be considered for DOAC therapy." [2] That monitoring burden has indirect costs (time off work, travel, lab fees) not captured in drug copay comparisons.

When Warfarin Is Actually Appropriate

Warfarin remains first-line for patients with mechanical heart valves or moderate-to-severe mitral stenosis; DOACs including apixaban are contraindicated in those settings per FDA labeling. [1] For those patients, cost is not the deciding factor because the clinical choice is already made.

Eliquis Interactions and Contraindications Health Net Reviewers May Flag

PA reviewers sometimes flag potential interactions as a reason to require additional documentation. Prescribers should address the following proactively in the PA letter.

Major Drug Interactions

Strong dual inhibitors of CYP3A4 and P-gp (such as ketoconazole, itraconazole, ritonavir, and clarithromycin) increase apixaban exposure by approximately 2-fold; the FDA recommends a dose reduction to 2.5 mg twice daily when one of these agents is coadministered in an AF patient otherwise taking 5 mg twice daily. [1] Strong dual inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) reduce apixaban exposure by approximately 54% and should be avoided. [1]

Renal and Hepatic Considerations

Apixaban is approximately 27% renally cleared. No dose adjustment is required for mild-to-moderate CKD, but the drug should be used with caution in severe renal impairment (CrCl <15 mL/min) or end-stage renal disease. [1] Patients on dialysis were excluded from the ARISTOTLE trial, and the ACC/AHA guideline acknowledges limited data in that population. [2] For hemodialysis patients with AF, the prescriber's PA letter should cite the specific clinical rationale.

Alternatives Health Net May Prefer Over Eliquis

Understanding the formulary alternatives helps predict PA outcomes and informs the step-therapy documentation.

Rivaroxaban (Xarelto)

Rivaroxaban is a once-daily Factor Xa inhibitor approved for the same AF and VTE indications. The ROCKET-AF trial (N=14,264) tested rivaroxaban 20 mg once daily versus warfarin in non-valvular AF and found non-inferior stroke/systemic embolism rates (1.7 vs. 2.2% per year). [10] Some Health Net formularies place rivaroxaban on a lower tier than apixaban, making it the preferred DOAC in step therapy. Once-daily dosing may be preferred for adherence in some patients.

Warfarin

Warfarin is generic, typically under $10/month, and sits on Tier 1 of virtually every formulary. It remains clinically appropriate for many patients and is the step Health Net most commonly requires before approving Eliquis without additional medical documentation.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor available as 75 mg and 150 mg capsules. The RE-LY trial (N=18,113) showed that dabigatran 150 mg twice daily reduced stroke/systemic embolism by 34% versus warfarin, though with a higher rate of gastrointestinal bleeding. [11] Like apixaban, it typically sits on a mid-to-high tier and requires PA on Health Net plans.

Special Populations and Coverage Nuances

Pediatric Patients

The FDA approved apixaban for pediatric patients aged 1 and older for VTE treatment and prevention in 2023. [1] Pediatric dosing is weight-based. Health Net PA for pediatric apixaban will require documentation of body weight and the specific dosing calculation. Very few formularies have updated pediatric-specific PA criteria, so prescribers should expect a peer-to-peer call.

Patients With Cancer-Associated VTE

The American Society of Clinical Oncology (ASCO) 2023 guidelines recommend DOACs, including apixaban, as preferred anticoagulation for cancer-associated VTE in patients without high bleeding-risk GI or genitourinary tumors. [12] That ASCO recommendation strengthens a PA letter for an oncology patient because it represents a major society guideline endorsement distinct from the AF indication.

Post-Surgical Prophylaxis

For patients who have just had hip or knee replacement surgery, apixaban 2.5 mg twice daily for 10 to 35 days is FDA-labeled. [1] Hospital-initiated therapy often bypasses outpatient PA because the inpatient fill is covered under the medical benefit; the challenge arises at the first outpatient fill. Prescribers should pre-submit the PA before discharge.

What the Research Says About DOAC Non-Adherence Due to Cost

Cost-related non-adherence to anticoagulation is not a theoretical concern. A 2019 analysis published in the Journal of the American College of Cardiology (N=30,000+ AF patients) found that patients with higher out-of-pocket DOAC costs had a 12% lower medication possession ratio compared with patients with lower cost-sharing, with associated increases in stroke hospitalization rates. [13] That real-world data supports the clinical case for aggressive insurance navigation rather than substituting a lower-cost agent when apixaban is the preferred clinical choice.

The American Heart Association's 2024 policy statement on cardiovascular medication access stated: "Barriers to affordable anticoagulation in atrial fibrillation translate directly into preventable ischemic strokes, which carry average acute hospitalization costs exceeding $20,000." [14] The economic argument for insurers to cover DOACs is therefore not only clinical but financial.